We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+14.46%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$257M
AUM Growth
-$6.27M
Cap. Flow
-$29.2M
Cap. Flow %
-11.36%
Top 10 Hldgs %
53.62%
Holding
74
New
14
Increased
16
Reduced
17
Closed
18

Top Buys

Rank Stock Value
1
ADMS
Adamas Pharmaceuticals
ADMS
+$3.75M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.53M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$3.48M
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$3.35M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.35M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.04M
2
VTRS icon
Viatris
VTRS
+$5.43M
3
SHPG
Shire pic
SHPG
+$5.4M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$5.01M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$4.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$26.3M 10.24%
180,522
+3,000
+2% +$409K
BIIB icon
2
Biogen
BIIB
$32.7B
$22.4M 8.71%
71,508
+10,400
+17% +$3.08M
REGN icon
3
Regeneron Pharmaceuticals
REGN
$83.1B
$18.3M 7.11%
40,830
-7,300
-15% -$3.47M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$139B
$13.5M 5.25%
88,722
-46,800
-35% -$7.04M
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$12.9M 5.03%
92,141
-4,500
-5% -$611K
INCY icon
6
Incyte
INCY
$25.9B
$10.4M 4.04%
88,975
+11,500
+15% +$1.45M
GILD icon
7
Gilead Sciences
GILD
$185B
$9.95M 3.87%
122,784
+1,000
+0.8% +$76.5K
ACAD icon
8
Acadia Pharmaceuticals
ACAD
$5.13B
$9.07M 3.53%
240,773
+103,000
+75% +$3.35M
ADMS
9
DELISTED
Adamas Pharmaceuticals
ADMS
$8.25M 3.21%
390,000
+204,766
+111% +$3.75M
AMGN icon
10
Amgen
AMGN
$236B
$6.73M 2.62%
36,104
-14,000
-28% -$2.48M
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$12.6B
$6.36M 2.48%
68,384
-49,782
-42% -$4.4M
ENTL
12
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$6.3M 2.45%
341,468
– –
EXEL icon
13
Exelixis
EXEL
$13.7B
$6.16M 2.4%
254,334
+47,334
+23% +$1.26M
XLRN
14
DELISTED
Acceleron Pharma
XLRN
$5.75M 2.24%
153,633
-24,010
-14% -$833K
SRPT icon
15
Sarepta Therapeutics
SRPT
$2.28B
$5.49M 2.14%
121,000
+60,000
+98% +$2.4M
PRTK
16
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5.07M 1.97%
202,000
+144,000
+248% +$3.35M
HALO icon
17
Halozyme
HALO
$12.1B
$4.91M 1.91%
282,633
+78,000
+38% +$1.06M
ALNY icon
18
Alnylam Pharmaceuticals
ALNY
$31.6B
$4.85M 1.89%
+41,300
New +$3.53M
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
$4.61M 1.8%
56,000
+21,000
+60% +$1.66M
TSRO
20
DELISTED
TESARO, Inc.
TSRO
$4.52M 1.76%
35,000
+1,500
+4% +$186K
SGMO
21
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.09M 1.59%
+273,000
New +$3.02M
NBIX icon
22
Neurocrine Biosciences
NBIX
$15.8B
$4.04M 1.57%
+66,000
New +$3.48M
LGND icon
23
Ligand Pharmaceuticals
LGND
$5.67B
$3.95M 1.54%
46,487
+32,060
+222% +$2.54M
FPRX
24
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3.54M 1.38%
86,500
+45,500
+111% +$1.43M
SGEN
25
DELISTED
Seagen Inc. Common Stock
SGEN
$3.13M 1.22%
57,500
-7,500
-12% -$384K
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2017 Portfolio in Review

As of Q3 2017, International Biotechnology Trust held 74 positions worth $257M, down 2.4% from $263M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

International Biotechnology Trust withdrew a net $29.2M in Q3 2017, closing 18 positions and reducing 17 holdings. Its most notable exit was Viatris, an estimated $5.43M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Alnylam Pharmaceuticals worth $4.85M.

  • International Biotechnology Trust's largest Q3 2017 buy was Alnylam Pharmaceuticals: 41,300 shares worth $4.85M.
  • International Biotechnology Trust added most to Adamas Pharmaceuticals in Q3 2017, an estimated $3.75M increase.
  • International Biotechnology Trust's biggest Q3 2017 reduction was Vertex Pharmaceuticals, cutting an estimated $7.04M.
  • International Biotechnology Trust fully exited Viatris in Q3 2017, selling an estimated $5.43M.
  • International Biotechnology Trust's ten largest holdings make up 54% of its $257M portfolio in Q3 2017.
  • International Biotechnology Trust opened 14 new positions and closed 18 in Q3 2017.
  • International Biotechnology Trust's portfolio value fell 2.4% quarter-over-quarter to $257M.

Based on International Biotechnology Trust's 13F filing for Q3 2017, filed 2 Mar 2018.